Imexpharm (IMP) Executives Register to Sell Shares for Personal Financial Planning

Overview

Three senior executives of Imexpharm (IMP), including the CEO and two Deputy CEOs, have registered to sell IMP shares totaling 607,400 units from mid-April to mid-May 2026, citing personal financial planning. The HoSE-listed pharmaceutical company concurrently announced ambitious 2026 business targets, including record revenue and profit, ahead of its annual shareholder meeting on April 22.

Key Facts

• CEO Trần Thị Đào registered to sell 371,400 IMP shares, reducing her stake from 0.44% to 0.2% of charter capital.
• Deputy CEO Ngô Minh Tuấn registered to sell 156,000 shares, lowering his holding to 150,000 shares (approximately 0.1%).
• Deputy CEO Huỳnh Văn Nhung registered to sell 80,000 shares, decreasing his stake to 100,000 shares (0.065%).
• All sales are scheduled between April 15 and May 15, 2026, with “personal financial planning” cited as the reason.
• Imexpharm targets 2026 revenue of VND 3,200 billion (+9.8% year-on-year) and pre-tax profit of VND 502 billion (+12.6%).
• The company plans to increase its 2025 cash dividend from 5% to 6% and proposes a 2026 dividend range of 5-8% in cash.
• The annual shareholder meeting is scheduled for April 22, 2026, in Hồ Chí Minh City.

What Happened

According to regulatory filings, three Imexpharm executives have formally registered to sell company shares. Board member and CEO Trần Thị Đào plans to sell 371,400 IMP shares, which would reduce her ownership from 671,400 shares (0.44% of charter capital) to 300,000 shares (0.2%). Similarly, Deputy CEO Ngô Minh Tuấn registered to sell 156,000 shares, bringing his holding down to 150,000 shares (approximately 0.1%). Another Deputy CEO, Huỳnh Văn Nhung, separately registered to sell 80,000 shares, decreasing his stake to 100,000 shares (0.065%). All transactions are scheduled between mid-April and mid-May 2026, with “personal financial planning” stated as the rationale.

The share-sale registrations coincide with the company’s disclosure of its 2026 business plan. Imexpharm aims for revenue of VND 3,200 billion and pre-tax profit of VND 502 billion in 2026, representing year-on-year increases of 9.8% and 12.6%, respectively. If achieved, these would be record highs for the company. The board also proposed increasing the 2025 cash dividend from 5% to 6% and indicated a 2026 dividend range of 5-8% in cash. These plans will be discussed at the annual shareholder meeting on April 22, 2026.

Market Context

Imexpharm (IMP) trades on the Ho Chi Minh Stock Exchange (HoSE) under the Pharmaceuticals sector. The stock closed at VND 56 on April 10, 2026, down 0.18% on volume of 24,200 shares. Insider selling activity often draws investor scrutiny, particularly when multiple executives register sales within a narrow timeframe. The company’s simultaneous release of aggressive growth targets and dividend proposals may counterbalance potential negative sentiment from the share-sale announcements.

Strategic Significance

The executive share sales, while framed as personal financial decisions, occur as Imexpharm projects its strongest-ever financial performance for 2026. For long-term investors, the key question is whether management’s bullish outlook aligns with their personal portfolio actions. The proposed dividend increases and record profit targets suggest confidence in operational execution, but the concentrated selling by top leadership warrants monitoring of subsequent insider transactions and business performance against these ambitious goals.

What to Watch

• Execution of the registered share sales between April 15 and May 15, 2026.
• Imexpharm’s Q1 2026 earnings report to assess progress toward the VND 3,200 billion revenue target.
• Shareholder approval of the 2025 dividend increase and 2026 dividend proposal at the April 22 annual meeting.
• Any further insider trading filings from Imexpharm executives in the coming quarters.
• The company’s actual 2026 financial results versus the projected VND 502 billion pre-tax profit.